IP Library Granted Patent US 9,248,217
Granted Patent B2
US 9,248,217 · App. 11/669,937 · Granted Feb 2, 2016

Nanoparticle coating of surfaces

Inventors: Robert A. Hoerr (Shoreview, MN); John V. Carlson (St. Michael, MN)
Assignee: Nanocopocia, LLC
A61L29/085A61L27/34A61L27/54A61L29/16A61L31/10A61L31/16G02C7/04A61F2/00A61L2300/404A61L2300/41A61L2300/416A61L2300/45A61L2300/602A61L2300/624A61L2400/12B05B5/025B05B5/03B05B5/08B05B7/061B05D1/04B05D1/06B05D2258/00B05D2451/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,248,217
App. No.
11/669,937
Granted
Feb 2, 2016
Kind
B2
Abstract

A nanoparticle coated hydrogel may be formed by a method of electrospraying nanoparticles on to a hydrogel surface includes providing a drug and polymer combination in solvent to an inner capillary of a coaxial capillary spray nozzle. A coating with a drug that releases over time may be provided. Open and closed matrixes may be selectively formed to help modify time release periods.

Claims (30)

1. An article comprising:

a hydrogel; and

a nanoparticle coating adhered to the hydrogel, the coating comprising first nanoparticles comprising a first biologically active organic material and a first polymer, the first biologically active material being encapsulated by the first polymer, the first nanoparticles having a nominal diameter of less than 500 nanometers.

2. The article of claim 1 , wherein the first biologically active organic material comprises a hydrophobic drug.

3. The article of claim 1 , wherein the first biologically active material releases from the coating over time when the article is placed in a moist environment.

4. The article of claim 1 , wherein the coating further comprises a polymer stabilizing material.

5. The article of claim 1 , wherein the first polymer comprises polyurethane, poly(lactide-co-caprolactone), polyisobutylene, or a combination thereof.

6. The article of claim 1 , wherein the first biologically active organic material is selected from the group consisting of an anti-inflammatory drug, an antimicrobial drug, an anti-proliferative drug, and combinations thereof.

7. The article of claim 1 , wherein the coating further comprises a second biologically active organic material different from the first biologically active organic material.

8. The article of claim 1 , wherein the hydrogel is in the form of a preformed hydrogel.

9. The article of claim 1 , wherein the coating is in the form of an open matrix.

10. The article of claim 1 , wherein the coating is in the form of an intermediate matrix.

11. The article of claim 1 , wherein the coating comprises a first layer and a second layer, the first layer comprising the first nanoparticles and the second layer comprising second nanoparticles comprising a second polymer and a second biologically active organic material encapsulated by the second polymer, the second biologically active organic material being different from the first biologically active organic material.

12. The article of claim 11 , wherein the first layer exhibits a first morphology and the second layer exhibits a second morphology different from the first morphology.

13. The article of claim 12 , wherein the morphology of the first and second layers is independently selected from the group consisting of an open matrix, an intermediate matrix and a closed matrix.

14. The article of claim 1 , wherein the first polymer comprises a biodegradable polymer.

15. The article of claim 1 , wherein the nanoparticles comprise spherical nanoparticles.

16. The article of claim 1 , wherein the nanoparticles comprise elongated fibrous nanoparticles.

17. The article of claim 1 , wherein the first biologically active organic material is a drug and the coating comprises

a first layer comprising the first nanoparticles, and

a second layer comprising second nanoparticles comprising a second drug and a second polymer, the second drug being different from the first drug.

18. The article of claim 17 , wherein the first layer exhibits a first release profile and the second layer exhibits a second release profile different from the first release profile.

19. The article of claim 18 , wherein the first release profile is rapid relative to the second release profile and the second release profile is delayed relative to the first release profile.

20. The article of claim 17 , wherein the first layer releases substantially all of the first drug within no greater than a few hours.

21. The article of claim 20 , wherein the second layer releases the second drug over a period of at least two weeks.

22. The article of claim 1 , wherein the first nanoparticles are formed by a coaxial nozzle electronanospray device.

23. The article of claim 1 , wherein the biologically active organic material comprises a drug and the first nanoparticles are derived from a composition comprising the drug, the first polymer, and a solvent.

24. The article of claim 23 , wherein the first nanoparticles are formed by delivering the composition to an inner capillary of a coaxial capillary spray nozzle.

25. The article of claim 1 , wherein the nanoparticle coating comprises a layer that is several nanoparticles deep.

26. The article of claim 1 , wherein the polymer comprises a hydrophobic polymer.

Assignments (8)
CHANGE OF NAME Recorded Apr 9, 2025
From: PXMMI, LLC
To: FLEX PHARMA, LLC
Reel/Frame 070792/0850 →
NUNC PRO TUNC ASSIGNMENT Recorded Apr 8, 2025
From: NANOCOPOEIA, LLC
To: PXMMI, LLC
Reel/Frame 070766/0704 →
SECURITY INTEREST Recorded Mar 27, 2025
From: PXMMI, LLC
To: DAVID R. FRAUENSHUH, SOLELY IN HIS CAPACITY AS TRUSTEE OF THE DAVID R. FRAUENSHUH REVOCABLE TRUST DATED MARCH 16, 1990
Reel/Frame 070666/0179 →
AFFIDAVIT RE: ASSGNMENT FOR THE BENEFIT OF CREDITORS (MINNESOTA STATE COURT FILE NO. 62-CV-24-5879) Recorded Mar 11, 2025
From: NANOCOPOEIA, LLC
To: LIGHTHOUSE MANAGEMENT GROUP, INC.
Reel/Frame 070542/0880 →
AFFIDAVIT RE: ASSGNMENT FOR THE BENEFIT OF CREDITORS (MINNESOTA STATE COURT FILE NO. 62-CV-24-5879) Recorded Mar 11, 2025
From: LIGHTHOUSE MANAGEMENT GROUP, INC.
To: NANOCOPOEIA, LLC
Reel/Frame 070735/0519 →
CHANGE OF ADDRESS Recorded Sep 14, 2021
From: NANOCOPOEIA, LLC
To: NANOCOPOEIA, LLC
Reel/Frame 057500/0557 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2016
From: NANOCOPOEIA, INC.
To: NANOCOPOEIA, LLC.
Reel/Frame 037683/0458 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 10, 2007
From: HOERR, ROBERT A.; CARLSON, JOHN V.
To: NANOCOPOEIA, INC.
Reel/Frame 019684/0701 →
Continuity (3)
Provisional Application 60838708 · Aug 18, 2006
Provisional Application 60764229 · Jan 31, 2006
Related Publication 20070278103A1 · Dec 6, 2007